Gabapentin may be an effective and well-tolerated treatment for patients with refractory chronic cough, according to a study published August 28 in The Lancet.
Gabapentin may be an effective and well-tolerated treatment for patients with refractory chronic cough, according to a study published August 28 in The Lancet.
Over a 2-year period, Nicole M. Ryan, PhD, of The University of Newcastle and John Hunter Hospital in NSW, Australia, and colleagues recruited 62 adult patients with refractory chronic cough lasting longer than 8 weeks from the John Hunter Hospital respiratory outpatient clinic. Patients were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1,800 mg) or matching placebo for 10 weeks.
The researchers noted that gabapentin significantly improved cough-specific quality of life compared with placebo. Ten patients (31%) experienced side effects, the most common being nausea and fatigue compared with 3 patients (10%) in the placebo group.
These positive effects suggest that central reflex sensitization is a relevant mechanism in refractory chronic cough, and that gabapentin might be an effective therapy, the authors wrote.
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More